BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaido T, Ogawa K, Mori A, Fujimoto Y, Ito T, Tomiyama K, Takada Y, Uemoto S. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery. 2013;154:1053-1060. [PMID: 24074704 DOI: 10.1016/j.surg.2013.04.056] [Cited by in Crossref: 75] [Cited by in F6Publishing: 74] [Article Influence: 9.4] [Reference Citation Analysis]
Number Citing Articles
1 Citores MJ, Lucena JL, de la Fuente S, Cuervas-Mons V. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation. World J Hepatol 2019;11:50-64. [PMID: 30705718 DOI: 10.4254/wjh.v11.i1.50] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
2 Hammad A, Kaido T, Ogawa K, Fujimoto Y, Uemura T, Mori A, Hatano E, Okajima H, Uemoto S. Liver transplantation for advanced hepatocellular carcinoma in patients with Child-Pugh A and B. Surg Today 2016;46:248-54. [PMID: 25721174 DOI: 10.1007/s00595-015-1142-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
3 Kurahashi S, Sano T, Natsume S, Senda Y, Yamaura H, Inaba Y, Shimizu Y. Surgical treatment after hepatic arterial infusion chemotherapy for hepatocellular carcinoma extending into the right atrium. Surg Case Rep 2015;1:47. [PMID: 26366344 DOI: 10.1186/s40792-015-0047-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Ersan V, Barut B, Yilmaz S. The Timing of Liver Transplantation Following Downstaging: Wait of Not to Wait? J Gastrointest Cancer 2020;51:1152-6. [PMID: 32856230 DOI: 10.1007/s12029-020-00491-z] [Reference Citation Analysis]
5 Guerrero-Misas M, Rodríguez-Perálvarez M, De la Mata M. Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol 2015;7:649-61. [PMID: 25866602 DOI: 10.4254/wjh.v7.i4.649] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
6 Isik B, Gonultas F, Sahin T, Yilmaz S. Microvascular Venous Invasion in Hepatocellular Carcinoma: Why Do Recurrences Occur? J Gastrointest Cancer 2020;51:1133-6. [PMID: 32839943 DOI: 10.1007/s12029-020-00487-9] [Reference Citation Analysis]
7 Na GH, Kim EY, Hong TH, You YK, Kim DG. Effects of loco regional treatments before living donor liver transplantation on overall survival and recurrence-free survival in South Korean patients with hepatocellular carcinoma. HPB (Oxford). 2016;18:98-106. [PMID: 26776857 DOI: 10.1016/j.hpb.2015.08.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
8 Shindoh J, Hashimoto M, Watanabe G. Surgical approach for hepatitis C virus-related hepatocellular carcinoma. World J Hepatol. 2015;7:70-77. [PMID: 25624998 DOI: 10.4254/wjh.v7.i1.70] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
9 Bento de Sousa JH, Calil IL, Tustumi F, da Cunha Khalil D, Felga GEG, de Arruda Pecora RA, de Almeida MD. Comparison between Milan and UCSF criteria for liver transplantation in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Transl Gastroenterol Hepatol. 2021;6:11. [PMID: 33409405 DOI: 10.21037/tgh.2020.01.06] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;104:1136-42. [DOI: 10.1097/tp.0000000000003174] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 16.0] [Reference Citation Analysis]
11 Akbulut S, Koc C. Do We Need to Be Limited by Matching Milan Criteria for Survival in Living Donor Liver Transplantation? J Gastrointest Cancer 2020;51:1107-13. [PMID: 32857265 DOI: 10.1007/s12029-020-00482-0] [Reference Citation Analysis]
12 Abreu P, Gorgen A, Oldani G, Hibi T, Sapisochin G. Recent advances in liver transplantation for cancer: The future of transplant oncology. JHEP Rep 2019;1:377-91. [PMID: 32039389 DOI: 10.1016/j.jhepr.2019.07.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
13 Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatol. 2014;25:154-159. [PMID: 27335840 DOI: 10.1155/2014/706945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
14 Bhatti ABH, Naqvi W, Khan NY, Zia HH, Dar FS, Khan ZA, Rana A. Living donor liver transplantation for advanced hepatocellular carcinoma including macrovascular invasion. J Cancer Res Clin Oncol 2021. [PMID: 34117916 DOI: 10.1007/s00432-021-03665-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Sarno G, Montalti R, Giglio MC, Rompianesi G, Tomassini F, Scarpellini E, De Simone G, De Palma GD, Troisi RI. Hepatocellular carcinoma in patients with chronic renal disease: Challenges of interventional treatment. Surg Oncol. 2021;36:42-50. [PMID: 33307490 DOI: 10.1016/j.suronc.2020.11.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Pinheiro RS, Waisberg DR, Nacif LS, Rocha-Santos V, Arantes RM, Ducatti L, Martino RB, Lai Q, Andraus W, D'Albuquerque LAC. Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure? Transl Gastroenterol Hepatol 2017;2:68. [PMID: 28905009 DOI: 10.21037/tgh.2017.08.02] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
17 Takada Y, Tohyama T, Watanabe J. Biological markers of hepatocellular carcinoma for use as selection criteria in liver transplantation. J Hepatobiliary Pancreat Sci 2015;22:279-86. [PMID: 25408520 DOI: 10.1002/jhbp.195] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
18 Mehta N. Hepatocellular Carcinoma-How to Determine Therapeutic Options. Hepatol Commun 2020;4:342-54. [PMID: 32140653 DOI: 10.1002/hep4.1481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
19 Togashi J, Akamastu N, Kokudo N. Living donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital. Hepatobiliary Surg Nutr. 2016;5:399-407. [PMID: 27826554 DOI: 10.21037/hbsn.2016.08.05] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
20 Fernandes ESM, Rodrigues PD, Álvares-da-Silva MR, Scaffaro LA, Farenzena M, Teixeira UF, Waechter FL. Treatment strategies for locally advanced hepatocellular carcinoma. Transl Gastroenterol Hepatol 2019;4:12. [PMID: 30976715 DOI: 10.21037/tgh.2019.01.02] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
21 Chen KD, Hsu CN, Wu YJ, Chu CH, Huang KT, Tsai MC, Chiu KW, Cheng BC, Chiu CH, Chen CL, Lin CC. The Perioperatively Altered Neutrophil-to-Lymphocyte Ratio Associates with Impaired DNA Damage Response in Liver Transplantation Recipients with Hepatocellular Carcinoma. Diagnostics (Basel) 2021;11:209. [PMID: 33573309 DOI: 10.3390/diagnostics11020209] [Reference Citation Analysis]
22 Qu Z, Ling Q, Gwiasda J, Xu X, Schrem H, Beneke J, Kaltenborn A, Krauth C, Mix H, Klempnauer J, Emmanouilidis N. Hangzhou criteria are more accurate than Milan criteria in predicting long-term survival after liver transplantation for HCC in Germany. Langenbecks Arch Surg 2018;403:643-54. [PMID: 30120543 DOI: 10.1007/s00423-018-1696-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
23 Harimoto N, Yoshida Y, Kurihara T, Takeishi K, Itoh S, Harada N, Tsujita E, Yamashita YI, Uchiyama H, Soejima Y, Ikegami T, Yoshizumi T, Kawanaka H, Ikeda T, Shirabe K, Saeki H, Oki E, Kimura Y, Maehara Y. Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma. Transplant Proc 2015;47:703-4. [PMID: 25819732 DOI: 10.1016/j.transproceed.2014.09.178] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Kumaran V. Role of liver transplantation for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S97-S103. [PMID: 25755618 DOI: 10.1016/j.jceh.2014.01.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
25 Yao FY, Fidelman N, Mehta N. The Key Role of Staging Definitions for Assessment of Downstaging for Hepatocellular Carcinoma. Semin Liver Dis 2021;41:117-27. [PMID: 33788207 DOI: 10.1055/s-0040-1716565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Levi Sandri GB, Rayar M, Qi X, Lucatelli P. Liver transplant for patients outside Milan criteria. Transl Gastroenterol Hepatol 2018;3:81. [PMID: 30505968 DOI: 10.21037/tgh.2018.10.03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
27 Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant 2020;20:333-47. [PMID: 31710773 DOI: 10.1111/ajt.15697] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
28 Daoud A, Soliman K, Teeter L, Ali H, Graviss EA, Mogawer S, Sholkamy A, El-Shazli M, Gaber AO. Alpha-Fetoprotein as a Modifier of Anatomic Criteria for Transplantation of HCC Patients. Transplant Proc 2021;53:833-8. [PMID: 33589231 DOI: 10.1016/j.transproceed.2021.01.024] [Reference Citation Analysis]
29 Kaido T, Morita S, Tanaka S, Ogawa K, Mori A, Hatano E, Uemoto S. Long-term outcomes of hepatic resection versus living donor liver transplantation for hepatocellular carcinoma: a propensity score-matching study. Dis Markers 2015;2015:425926. [PMID: 25922554 DOI: 10.1155/2015/425926] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
30 Lee HW, Song G, Lee S, Kim JM, Joh J, Han DH, Kim SI, Kim SH, Kim D, Cho JY, Suh K. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma: Lee et al. Liver Transpl 2018;24:1243-51. [DOI: 10.1002/lt.25056] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
31 Bhangui P, Saigal S, Gautam D, Piplani T, Choudhary N, Chaudhary R, Yadav S, Thiagarajan S, Rastogi A, Saraf N, Nundy S, Soin AS. Incorporating Tumor Biology to Predict Hepatocellular Carcinoma Recurrence in Patients Undergoing Living Donor Liver Transplantation Using Expanded Selection Criteria. Liver Transpl 2021;27:209-21. [PMID: 33253492 DOI: 10.1002/lt.25956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
32 Firl DJ, Sasaki K, Agopian VG, Gorgen A, Kimura S, Dumronggittigule W, Mcvey JC, Iesari S, Mennini G, Vitale A, Finkenstedt A, Onali S, Hoppe‐lotichius M, Vennarecci G, Manzia TM, Nicolini D, Avolio AW, Agnes S, Vivarelli M, Tisone G, Ettorre GM, Otto G, Tsochatzis E, Rossi M, Viveiros A, Cillo U, Markmann JF, Ikegami T, Kaido T, Lai Q, Sapisochin G, Lerut J, Aucejo FN; on behalf of the European Hepatocellular Cancer Liver Transplant Study Group. Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients. Hepatology 2019;71:569-82. [DOI: 10.1002/hep.30838] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
33 Kamo N, Kaido T, Yagi S, Okajima H, Uemoto S. Liver transplantation for small hepatocellular carcinoma. Hepatobiliary Surg Nutr 2016;5:391-8. [PMID: 27826553 DOI: 10.21037/hbsn.2016.05.03] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
34 She WH, Chan ACY, Cheung TT, Lo CM, Chok KSH. Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels. World J Hepatol. 2018;10:308-318. [PMID: 29527266 DOI: 10.4254/wjh.v10.i2.308] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
35 Kamo N, Kaido T, Yagi S, Okajima H, Uemoto S. Liver Transplantation for Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer 2018;7:179-89. [PMID: 29888207 DOI: 10.1159/000487058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
36 Na GH, Kim DG, Han JH, Kim EY, Lee SH, Hong TH, You YK. Inflammatory markers as selection criteria of hepatocellular carcinoma in living-donor liver transplantation. World J Gastroenterol. 2014;20:6594-6601. [PMID: 24914382 DOI: 10.3748/wjg.v20.i21.6594] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
37 Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122:3430-3446. [PMID: 27622302 DOI: 10.1002/cncr.30237] [Cited by in Crossref: 106] [Cited by in F6Publishing: 95] [Article Influence: 21.2] [Reference Citation Analysis]
38 Uchiyama H, Itoh S, Yoshizumi T, Ikegami T, Harimoto N, Soejima Y, Harada N, Morita K, Toshima T, Motomura T. Living donor liver transplantation for hepatocellular carcinoma: results of prospective patient selection by Kyushu University Criteria in 7 years. HPB (Oxford). 2017;19:1082-1090. [PMID: 28888776 DOI: 10.1016/j.hpb.2017.08.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
39 Santopaolo F, Lenci I, Milana M, Manzia TM, Baiocchi L. Liver transplantation for hepatocellular carcinoma: Where do we stand? World J Gastroenterol 2019;25:2591-602. [PMID: 31210712 DOI: 10.3748/wjg.v25.i21.2591] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
40 Mehta N, Yao FY. What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma? Clin Liver Dis (Hoboken) 2019;13:20-5. [PMID: 31168361 DOI: 10.1002/cld.793] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
41 Lee HW, Suh K. Advancements of liver transplantation for hepatocellular carcinoma in Korea. Japanese Journal of Clinical Oncology 2017;47:93-100. [DOI: 10.1093/jjco/hyw168] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
42 Soriano A, Varona A, Gianchandani R, Moneva ME, Arranz J, Gonzalez A, Barrera M. Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future. World J Hepatol 2016;8:58-68. [PMID: 26783421 DOI: 10.4254/wjh.v8.i1.58] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
43 Akamatsu N, Sugawara Y, Kokudo N. Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer. 2014;3:108-118. [PMID: 24945001 DOI: 10.1159/000343866] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
44 Yoon YI, Lee SG. Living Donor Liver Transplantation for Hepatocellular Carcinoma: An Asian Perspective. Dig Dis Sci 2019;64:993-1000. [PMID: 30895483 DOI: 10.1007/s10620-019-05551-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
45 Sasaki K, Morioka D, Conci S, Margonis GA, Sawada Y, Ruzzenente A, Kumamoto T, Iacono C, Andreatos N, Guglielmi A, Endo I, Pawlik TM. The Tumor Burden Score: A New “Metro-ticket” Prognostic Tool For Colorectal Liver Metastases Based on Tumor Size and Number of Tumors. Annals of Surgery 2018;267:132-41. [DOI: 10.1097/sla.0000000000002064] [Cited by in Crossref: 72] [Cited by in F6Publishing: 24] [Article Influence: 24.0] [Reference Citation Analysis]
46 Lee HW, Suh KS. Liver transplantation for advanced hepatocellular carcinoma. Clin Mol Hepatol 2016;22:309-18. [PMID: 27729631 DOI: 10.3350/cmh.2016.0042] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
47 Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. [DOI: 10.1136/bmj.m3544] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
48 Pavel MC, Fuster J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. World J Gastroenterol 2018;24:3626-36. [PMID: 30166858 DOI: 10.3748/wjg.v24.i32.3626] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
49 Yaprak O, Acar S, Ertugrul G, Dayangac M. Role of pre-transplant 18F-FDG PET/CT in predicting hepatocellular carcinoma recurrence after liver transplantation. World J Gastrointest Oncol 2018;10:336-43. [PMID: 30364796 DOI: 10.4251/wjgo.v10.i10.336] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
50 Na GH, Hong TH, You YK, Kim DG. Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation. World J Gastroenterol 2016;22:5790-9. [PMID: 27433092 DOI: 10.3748/wjg.v22.i25.5790] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
51 Kwong A, Mehta N. Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma: Is There a Limit? Clin Liver Dis 2021;25:19-33. [PMID: 33978578 DOI: 10.1016/j.cld.2020.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Mehta N, Yao FY. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)? Liver Transpl. 2018;24:327-329. [PMID: 29351366 DOI: 10.1002/lt.25017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
53 Ogawa K, Takada Y. Living vs. deceased-donor liver transplantation for patients with hepatocellular carcinoma. Transl Gastroenterol Hepatol 2016;1:35. [PMID: 28138602 DOI: 10.21037/tgh.2016.04.03] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
54 Hibi T, Itano O, Shinoda M, Kitagawa Y. Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun. Surg Today 2017;47:403-15. [PMID: 27130463 DOI: 10.1007/s00595-016-1337-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
55 Moghe A, Ganesh S, Humar A, Molinari M, Jonassaint N. Expanding Donor Selection and Recipient Indications for Living Donor Liver Transplantation. Clin Liver Dis 2021;25:121-35. [PMID: 33978574 DOI: 10.1016/j.cld.2020.08.011] [Reference Citation Analysis]
56 Grąt M, Kornasiewicz O, Lewandowski Z, Hołówko W, Grąt K, Kobryń K, Patkowski W, Zieniewicz K, Krawczyk M. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg 2014;38:2698-707. [PMID: 24858191 DOI: 10.1007/s00268-014-2647-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
57 Chu KK, Wong KH, Chok KS. Expanding Indications for Liver Transplant: Tumor and Patient Factors. Gut Liver 2021;15:19-30. [PMID: 32102130 DOI: 10.5009/gnl19265] [Reference Citation Analysis]
58 Lee HW, Suh KS. Expansion of the criteria for living donor liver transplantation for hepatocellular carcinoma. Curr Opin Organ Transplant. 2016;21:231-237. [PMID: 26918880 DOI: 10.1097/mot.0000000000000294] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
59 Shimamura T, Akamatsu N, Fujiyoshi M, Kawaguchi A, Morita S, Kawasaki S, Uemoto S, Kokudo N, Hasegawa K, Ohdan H, Egawa H, Furukawa H, Todo S;  Japanese Liver Transplantation Society. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study. Transpl Int. 2019;32:356-368. [PMID: 30556935 DOI: 10.1111/tri.13391] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 17.0] [Reference Citation Analysis]
60 Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N, Milicevic M. Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol. 2015;7:2274-2291. [PMID: 26380652 DOI: 10.4254/wjh.v7.i20.2274] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
61 Bhatti ABH, Qureshi AI, Tahir R, Dar FS, Khan NY, Zia HH, Riyaz S, Rana A. When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma. BMC Cancer. 2020;20:754. [PMID: 32787864 DOI: 10.1186/s12885-020-07238-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
62 Hibi T, Shinoda M, Itano O, Kitagawa Y. Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine. Organogenesis 2014;10:241-9. [PMID: 24836922 DOI: 10.4161/org.29245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
63 Panayotova G, Lunsford KE, Latt NL, Paterno F, Guarrera JV, Pyrsopoulos N. Expanding indications for liver transplantation in the era of liver transplant oncology. World J Gastrointest Surg 2021;13:392-405. [PMID: 34122730 DOI: 10.4240/wjgs.v13.i5.392] [Reference Citation Analysis]
64 Court CM, Harlander-Locke MP, Markovic D, French SW, Naini BV, Lu DS, Raman SS, Kaldas FM, Zarrinpar A, Farmer DG, Finn RS, Sadeghi S, Tomlinson JS, Busuttil RW, Agopian VG. Determination of hepatocellular carcinoma grade by needle biopsy is unreliable for liver transplant candidate selection. Liver Transpl. 2017;23:1123-1132. [PMID: 28688158 DOI: 10.1002/lt.24811] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
65 Kaido T. Recent evolution of living donor liver transplantation at Kyoto University: How to achieve a one-year overall survival rate of 99%? Hepatobiliary & Pancreatic Diseases International 2020;19:328-33. [DOI: 10.1016/j.hbpd.2020.06.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
66 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 127] [Article Influence: 36.5] [Reference Citation Analysis]
67 Frankul L, Frenette C. Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. J Clin Transl Hepatol. 2021;9:220-226. [PMID: 34007804 DOI: 10.14218/jcth.2020.00037] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Limkemann AJ, Abreu P, Sapisochin G. How far can we go with hepatocellular carcinoma in living donor liver transplantation?: . Current Opinion in Organ Transplantation 2019;24:644-50. [DOI: 10.1097/mot.0000000000000692] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
69 Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology 2019;69:1193-205. [PMID: 30548884 DOI: 10.1002/hep.30413] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
70 Kaido T. Selection Criteria and Current Issues in Liver Transplantation for Hepatocellular Carcinoma. Liver Cancer 2016;5:121-7. [PMID: 27386430 DOI: 10.1159/000367749] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
71 Wang L, Wang J, Zhang X, Li J, Wei X, Cheng J, Ling Q, Xie H, Zhou L, Xu X, Zheng S. Diagnostic Value of Preoperative Needle Biopsy for Tumor Grading Assessment in Hepatocellular Carcinoma. PLoS One. 2015;10:e0144216. [PMID: 26658912 DOI: 10.1371/journal.pone.0144216] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
72 Lang SA, Bednarsch J, Czigany Z, Joechle K, Kroh A, Amygdalos I, Strnad P, Bruns T, Heise D, Ulmer F, Neumann UP. Liver transplantation in malignant disease. WJCO 2021;12:623-45. [DOI: 10.5306/wjco.v12.i8.623] [Reference Citation Analysis]
73 Lu D, Yang F, Zhuo J, Yang M, Lin Z, Jin P, Cai X, Cen B, Wang J, Wei X, Zheng S, Xu X. The Matching Status Between Donor and Recipient Hepatitis B Seroepidemiology Makes a Difference in Liver Transplantation for Hepatocellular Carcinoma. Clin Transl Gastroenterol 2020;11:e00168. [PMID: 32358239 DOI: 10.14309/ctg.0000000000000168] [Reference Citation Analysis]
74 Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res 2015;45:59-74. [PMID: 24965914 DOI: 10.1111/hepr.12378] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 7.4] [Reference Citation Analysis]